Industry News
Pharmaceutical Industry News
F.D.A. Panel Recommends Moderna Booster for Certain Groups
Those eligible for the extra shot would include adults over 65 and others at high risk — the same groups now eligible for a Pfizer-BioNTech boost
FDA panel backs half-dose Moderna booster for the elderly and others at high risk
FDA panel backs half-dose Moderna booster for the elderly and others at high risk kdunleavy Thu, 10/14/2021 - 17:00
F.D.A. Panel Greenlights Moderna Boosters for High-Risk Individuals
A Food and Drug Administration advisory panel recommended a half-dose as a third injection for people 65 and older as well as younger adults at high risk because of their medical conditions or jobs.
Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch
Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch nmissakian Thu, 10/14/2021 - 16:30
Where Things Stand on Boosters for Three Vaccines in the U.S.
Confused about who can get a booster shot of which vaccine, and what the F.D.A.’s advisers on vaccines are voting on this week? This scorecard may help.
Regeneron pushes its versatile antibody cocktail closer to finish line as a multi-use COVID treatment
Regeneron pushes its versatile antibody cocktail closer to finish line as a multi-use COVID treatment kdunleavy Thu, 10/14/2021 - 13:57
Regeneron pushes its versatile antibody cocktail closer to finish line as a multiuse COVID treatment
Regeneron pushes its versatile antibody cocktail closer to finish line as a multiuse COVID treatment kdunleavy Thu, 10/14/2021 - 13:57
A return to the top: Former FDA Commissioner Califf reportedly Biden’s pick for Woodcock’s role
A return to the top: Former FDA Commissioner Califf reportedly Biden's pick for Woodcock's role klahucik Thu, 10/14/2021 - 13:52
Merck bags imperfect immunotherapy first with Keytruda cervical cancer approval
Merck bags imperfect immunotherapy first with Keytruda cervical cancer approval aliu Thu, 10/14/2021 - 10:27
Bristol Myers Squibb is nixing BeiGene’s Abraxane deal in China amid manufacturing woes. Is their cancer rivalry really to blame?
Bristol Myers Squibb is nixing BeiGene's Abraxane deal in China amid manufacturing woes. Is their cancer rivalry really to blame? aliu Thu, 10/14/2021 - 09:34
Johnson & Johnson COVID-19 vax recipients see stronger response with Moderna, Pfizer boosters, study says, but notes comparison limitations
Johnson & Johnson COVID-19 vax recipients see stronger response with Moderna, Pfizer boosters, study says, but notes comparison limitations kdunleavy Thu, 10/14/2021 - 08:53
Avid Bioservices to build $75M plant in California for viral vectors, name new executive
Avid Bioservices to build $75M plant in California for viral vectors, name new executive jkeenan Thu, 10/14/2021 - 07:31
Healthcare marketing firm Relevate Health unveils brand refresh to highlight digital focus
Healthcare marketing firm Relevate Health unveils brand refresh to highlight digital focus nmissakian Wed, 10/13/2021 - 16:53
Novartis exec says COVID exposed pharma manufacturing weaknesses. Here’s how he plans to fix them
Novartis exec says COVID exposed pharma manufacturing weaknesses. Here's how he plans to fix them esagonowsky Wed, 10/13/2021 - 15:26
Aceto’s expansion roll continues with buyout of Irish biopharma manufacturer
Aceto's expansion roll continues with buyout of Irish biopharma manufacturer jkeenan Wed, 10/13/2021 - 14:12
Moderna criticized for COVID-19 vaccine strategy putting once feel-good success story in jeopardy
Moderna criticized for COVID-19 vaccine strategy putting once feel-good success story in jeopardy kdunleavy Wed, 10/13/2021 - 10:58
Johnson & Johnson, Moderna COVID-19 vaccines work as intended, FDA staff say ahead of high-stakes booster meeting
Johnson & Johnson, Moderna COVID-19 vaccines work as intended, FDA staff say ahead of high-stakes booster meeting esagonowsky Wed, 10/13/2021 - 10:40
ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadership
ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadership aliu Wed, 10/13/2021 - 10:11
Ardelyx axes 65% of workforce with no clarity from FDA on kidney drug’s future
Ardelyx axes 65% of workforce with no clarity from FDA on kidney drug's future klahucik Wed, 10/13/2021 - 09:36
FDA Form 483 puts a wrinkle into Revance’s application for Botox rival
FDA Form 483 puts a wrinkle into Revance's application for Botox rival jkeenan Wed, 10/13/2021 - 09:31